Psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis that can lead to joint deformity and disability. PsA has a low likelihood of clinical remission and cure. For a long time, therapeutic options for PsA patients have been unsatisfactory, but the introduction of anti-tumor necrosis factor agents have markedly improved articular and cutaneous signs and symptoms. The efficacy of tumor necrosis factor blockers also raised the bar for treatment goals in PsA. Remission may now be an attainable outcome in the treatment paradigm. At this time, specific tools to define PsA remission are not available. New assessments to define remission must be developed and incorporated into clinical trials and longitudinal registries.